The first patient has been enrolled in a Phase 2b trial of Evommune, Inc.’s EVO756, an oral small molecule antagonist of mas-related G-protein coupled receptor X2 (MRGPRX2), that targets moderate-to-severe atopic dermatitis (AD).
The Phase 2b trial of approximately 120 patients is a randomized, multi-center, double-blind, placebo-controlled, dose-ranging trial which will assess the efficacy and safety of EVO756 in adults with moderate-to-severe AD. Patients will be randomized to receive EVO756 or matching placebo for 12 weeks. The primary objective of this trial is to characterize the efficacy of multiple dose levels of EVO756 compared to placebo as assessed by the percentage change in Eczema Area and Severity Index (EASI) from Baseline to Week 12. A key secondary endpoint is the evaluation of Pruritus-Numerical Rating Scale (NRS).
“MRGPRX2 is one of the most important new targets in chronic inflammation, and we believe our industry leading development candidate, EVO756, has the potential to be a critically needed oral therapeutic for AD, as well as a broad range of other inflammatory diseases. We expect to have several potential clinical inflection points in 2026, as we now have two Phase 2 programs underway with EVO756 and EVO301 in AD, and continue to rapidly enroll patients in our chronic spontaneous urticaria Phase 2b trial of EVO756,” says Luis Peña, Chief Executive Officer at Evommune, in a news release.
Translational data generated by Evommune and others have demonstrated the increased presence of mast cells and MRGPRX2 ligands in AD diseased-tissue and lesions. In a Phase 2 trial with chronic inducible urticaria (symptomatic dermographism) patients, Evommune observed the role of MRGPRX2 antagonism in modulating neurogenic inflammation and mast cell activation. The Company believes that these data further support the rationale for the initiation of this trial in AD.
“There is still a significant need for better treatment options for AD patients, particularly for the intense itch which is the primary symptom driving patients to physicians. MRGPRX2 antagonism is exciting in its potential to change the paradigm as the first target that modulates both mast cells and sensory neurons,” adds Eugene Bauer, MD, Chief Medical Officer at Evommune.
